Stifel Nicolaus reaffirmed their buy rating on shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) in a research report sent to investors on Monday. Stifel Nicolaus currently has a $35.00 target price on the specialty pharmaceutical company’s stock.

VRX has been the topic of several other research reports. BidaskClub lowered Valeant Pharmaceuticals International from a hold rating to a sell rating in a research note on Friday, June 16th. Scotiabank decreased their price target on Valeant Pharmaceuticals International from $15.00 to $12.00 and set a sector perform rating on the stock in a research note on Wednesday, April 26th. Vetr lowered Valeant Pharmaceuticals International from a strong-buy rating to a buy rating and set a $14.82 price target on the stock. in a research note on Monday, May 22nd. Mizuho reaffirmed an underperform rating and issued a $8.00 price target (down previously from $9.00) on shares of Valeant Pharmaceuticals International in a research note on Monday, April 17th. Finally, Wells Fargo & Company reaffirmed a sell rating on shares of Valeant Pharmaceuticals International in a research note on Tuesday, June 27th. Four analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of $16.81.

Shares of Valeant Pharmaceuticals International (NYSE VRX) traded down 1.21% during midday trading on Monday, reaching $17.16. The company’s stock had a trading volume of 13,133,660 shares. The stock has a 50 day moving average price of $14.80 and a 200-day moving average price of $13.19. Valeant Pharmaceuticals International has a 52-week low of $8.31 and a 52-week high of $32.74. The company’s market capitalization is $5.97 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.87 by $1.93. The business had revenue of $2.11 billion for the quarter, compared to analyst estimates of $2.17 billion. Valeant Pharmaceuticals International had a positive return on equity of 58.02% and a negative net margin of 14.96%. Valeant Pharmaceuticals International’s quarterly revenue was down 11.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.08) EPS. Equities research analysts expect that Valeant Pharmaceuticals International will post $3.89 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/07/18/valeant-pharmaceuticals-international-inc-vrx-receives-buy-rating-from-stifel-nicolaus.html.

In related news, Director Schutter Richard U. De acquired 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 11th. The stock was acquired at an average cost of $13.90 per share, with a total value of $278,000.00. Following the completion of the purchase, the director now directly owns 70,572 shares in the company, valued at $980,950.80. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 5.87% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. ValueAct Holdings L.P. boosted its position in Valeant Pharmaceuticals International by 20.0% in the first quarter. ValueAct Holdings L.P. now owns 17,997,224 shares of the specialty pharmaceutical company’s stock worth $198,509,000 after buying an additional 3,002,963 shares during the last quarter. Vanguard Group Inc. boosted its position in Valeant Pharmaceuticals International by 9.8% in the first quarter. Vanguard Group Inc. now owns 6,980,074 shares of the specialty pharmaceutical company’s stock worth $76,990,000 after buying an additional 621,618 shares during the last quarter. Bank of Montreal Can boosted its position in Valeant Pharmaceuticals International by 9.8% in the second quarter. Bank of Montreal Can now owns 6,330,670 shares of the specialty pharmaceutical company’s stock worth $109,521,000 after buying an additional 564,215 shares during the last quarter. OppenheimerFunds Inc. boosted its position in Valeant Pharmaceuticals International by 17.1% in the first quarter. OppenheimerFunds Inc. now owns 4,489,169 shares of the specialty pharmaceutical company’s stock worth $49,516,000 after buying an additional 656,116 shares during the last quarter. Finally, Morgan Stanley boosted its position in Valeant Pharmaceuticals International by 48.2% in the first quarter. Morgan Stanley now owns 2,777,063 shares of the specialty pharmaceutical company’s stock worth $30,631,000 after buying an additional 903,256 shares during the last quarter. 50.45% of the stock is owned by hedge funds and other institutional investors.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.